NBI6024
an altered-peptide ligand, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide
Networked: 3
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
1. | Type 1 Diabetes Mellitus (Autoimmune Diabetes)
11/01/2009
- " A total of 188 patients, aged 10-35 years, with recently diagnosed type 1 diabetes were randomly assigned for a treatment consisting of the subcutaneous administration of placebo or 1, 0.5, or 0.1 mg NBI-6024 at baseline, weeks 2 and 4, and then monthly until month 24. " 11/01/2009
- " This randomized, four-arm, placebo-controlled, dose-ranging phase 2 trial was conducted to determine whether repeated subcutaneous injections of the altered peptide ligand, NBI-6024, designed to inhibit autoreactive T-cells, improves beta-cell function in patients with recently diagnosed type 1 diabetes. " 11/01/2009
- " No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes." 07/01/2002
- " Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide." 01/01/2006
- " Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope."
|
|
Related Drugs and Biologics
Related Therapies and Procedures